Korea S.E.
23:00:00 30/05/2024 BST
5-day change
1st Jan Change
19,260
KRW
+2.07%
+2.88%
+19.18%
Tranche Update on DONGKOOK Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 7, 2014.
From May 7, 2014 to June 30, 2014, the company has repurchased 29,416 shares, representing 0.33% for KRW 831.7 million. With this, the company has completed the repurchase of 29,416 shares, representing 0.33% for KRW 831.7 million under the buyback announced on May 7, 2014.
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-16
CI
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
03-14
CI
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
11/08/23
CI
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/05/23
CI
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
14/11/22
CI
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
16/05/22
CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine
12/04/22
MT
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
17/03/22
CI
DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
15/11/21
CI
YJM Games Co., Ltd. announced that it has received KRW 7.5 billion in funding from HisStory Investment Management, DongKook Pharmaceutical Co., Ltd.
17/08/21
CI
YJM Games Co., Ltd. announced that it expects to receive KRW 7.5 billion in funding from HisStory Investment Management, DongKook Pharmaceutical Co., Ltd., and other investors
10/08/21
CI
Hanchang Corporation announced that it has received KRW 5 billion in funding from MAGNA Investment Co., Ltd., Axis Investment Co., Ltd., DongKook Pharmaceutical Co., Ltd., Jinhaksa Corporation
27/12/20
CI
Hanchang Corporation announced that it expects to receive KRW 5 billion in funding from MAGNA Investment Co., Ltd., Axis Investment Co., Ltd., DongKook Pharmaceutical Co., Ltd., Jinhaksa Corporation
22/12/20
CI
DongKook Pharmaceutical Co., Ltd. announced that it has received KRW 10.0000516 billion in funding
17/07/18
CI
DongKook Pharmaceutical Co., Ltd. announced that it expects to receive KRW 10.0000516 billion in funding
02/07/18
CI
GS Instruments Co. Ltd. announced that it has received KRW 3 billion in funding from DONGKOOK Pharmaceutical Co., Ltd., Unione Communications Co., Ltd., GS Teletech Co., Ltd., and other investors.
02/05/16
CI
GS Instruments Co. Ltd. announced that it expects to receive KRW 3 billion in funding from DONGKOOK Pharmaceutical Co., Ltd., Unione Communications Co., Ltd., GS Teletech Co., Ltd., and other investors.
05/04/16
CI
DONGKOOK Pharmaceutical Co., Ltd.'s Equity Buyback announced on March 13, 2015 has expired.
12/09/15
CI
DONGKOOK Pharmaceutical Co., Ltd.(KOSDAQ:A086450) added to Russell Global Index
29/06/15
CI
Tranche Update on DONGKOOK Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 13, 2015.
15/06/15
CI
DONGKOOK Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
12/03/15
CI
DONGKOOK Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
12/03/15
CI
DONGKOOK Pharmaceutical Co., Ltd.’s Equity Buyback announced on May 7, 2014 has expired with 33,046 shares, representing 0.37% for KRW 954.65 million.
06/11/14
CI
Tranche Update on DONGKOOK Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 7, 2014.
06/11/14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture and distribution of pharmaceuticals. The Company develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. It also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The Company distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.
More about the company
Last Close Price
19,260
KRW
Average target price
24,000
KRW
Spread / Average Target
+24.61%
Consensus
1st Jan change
Capi.
+19.18% 612M +40.73% 739B +32.83% 598B -6.30% 353B +15.15% 318B +4.05% 285B +15.00% 240B -5.52% 206B +6.17% 164B -0.45% 162B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
DONGKOOK PHARMACEUTICAL CO., LTD. 
